This EBMT activity report documents the haematopoietic stem cell transplantation (HSCT) activity in Europe in 2005. It provides numbers of HSCT by indication, donor type and stem cell source, lists the new practice of planned double transplants with allogeneic after autologous HSCT and concentrates on the increasing role of unrelated transplants over the last years. In 2005, there were 24 168 first HSCT, 8890 allogeneic (37%), 15 278 autologous (63%) and 3773 additional re-or multiple transplants reported from 597 centres in 43 participating countries. Main indications were leukaemias (7404 (31%; 82% allogeneic)); lymphomas (13 825 (57%; 89% autologous)); solid tumours (1655 (7%; 92% autologous)) and non-malignant disorders (1131 (5%; 93% allogeneic)). A total of 671 planned allogeneic after autologous HSCT were reported; the majority for myeloma (52%), lymphoma (28%) and acute myeloid leukaemia (11%). Compared to 2004, there was a 20% increase in allogeneic HSCT; numbers of autologous HSCT remained constant. The most noticeable increase was in unrelated HSCT, which comprise 41% of all allogeneic HSCT. Unrelated HSCT were preferentially performed for leukaemias and in countries with high income according to World Bank criteria. These data illustrate the current experience in Europe and form the basis for patient counselling and decisions making at health care institutions.
Introduction
Transplantation of haematopoietic stem cells (HSCT) has become the standard treatment for many patients with congenital or acquired disorders of the haematopoietic system or with chemo-, radio-or immunosensitive malignancies. [1] [2] [3] [4] It is under examination for novel indications such as autoimmune disorders or single enzyme deficiencies. [5] [6] [7] Its introduction to clinical medicine dates back to 1968 with the first reports of successful bone marrow transplants from human leucocyte antigen (HLA) identical siblings for patients with immune deficiency disorders. 8 Years of intensive investigations have improved outcome and triggered the wide application we see today. 9 HSCT has seen a rapid expansion and a constant evolution in technology use. Stem cell source has changed from bone marrow to peripheral blood and novel conditioning regimens have been introduced. [10] [11] [12] It is the purpose of this survey to provide precise data on the current use of HSCT and to illustrate the latest trends. Both are essential for patients, physicians and health care providers alike.
The activity survey of the European Group for Blood and Marrow Transplantation (EBMT) is a mandatory selfreporting system and forms an integral part of a comprehensive quality assurance programme JACIE (Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT)) (http://www.JACIE.org) and the European Group for Blood and Marrow Transplantation (EBMT) (http://www.EBMT.org). It was designed in 1990 to provide comprehensive information on transplant numbers and to distribute it rapidly on an annual basis. 13 EBMT members and affiliated teams known to perform transplants, report their numbers of patients transplanted by indication, stem cell source and donor type. For the 2005 survey, a new data set was introduced providing information on the increasingly reported use of planned double transplants with an autologous transplant first, followed by an allogeneic reduced intensity conditioning (RIC) transplant. In addition, this year's survey concentrates on the use of unrelated HSCT, its increase and its application by disease type. Furthermore, we were interested in the potential correlation with economic factors. We used the Gross National Income per capita (GNI/capita) in the participating European countries as a comparator.
Patients and methods

Data collection and validation
Participating teams reported their data for 2005 by indication, stem cell source and donor type as listed in Table 1 . Data were validated by three independent systems; through confirmation by the reporting team, which received a computer printout of the entered data, by selective comparison with MED-A data sets in the data capture system of the EBMT; PROMISE (www.msbi.nl/Promise) and by cross-checking with national registries where they exist. Onsite visits of selected teams were part of the quality control programme.
Teams
Six hundred and twenty two teams in 43 countries (38 European and five affiliated countries) were contacted for 798  2305  45  264  6  23  666  2000  97  1200  6107  1297  7404  Acute myeloid leukaemia  306  1128  18  138  2  12  223  875  70  801  2702  871  3573  First complete remission  240  702  8  43  2  5  107  341  58  668  1448  726  2174  Not first complete remission  66  426  10  95  7  116  534  12  133  1254  145  1399  Acute lymphatic leukaemia  274  415  16  85  1  5  234  438  21  168  1468  189  1657  First complete remission  186  257  4  23  1  2  118  200  17  122  791  139  930  Not first complete remission  88  158  12  62  3  116  238  4  46  677  50  727  Chronic myeloid leukaemia  129  249  2  16  0  2  85  201  0  17  684  17  701  Chronic phase  107  170  2  6  60  116  5  461  5  466  Not first chronic phase  22  79  10  2  25  85  12  223  12  235  MDS incl. Sec AL  67  271  7  12  2  1  85  286  3  28  731  31  762  MPS  10  74  1  4  1  27  108  2  8  225  10  235  Chronic lymphatic leukaemia  12  168  1  9  3  12  92  1  178  297  179  476   Lymphoproliferative disorders  97  800  4  36  0  17  88  478  118  12187  1520 12305 13825  Plasma cell disorders -MM  17  311  2  5  17  161  19  5768  513  5787 
Definitions
As their introduction the EBMT surveys have focused on numbers of patients, which were treated with HSCT. Information on additional transplants, hence on a second, third or fourth HSCT in a patient with a previous HSCT was collected in two forms. It was either reported by disease category with the newly introduced system for planned double allogeneic after autologous transplants or collected generically for all other situations. These were as follows: Re-transplants, (autologous or allogeneic) defined as an unplanned HSCT for rejection or relapse after a first HSCT or Multiple transplants, defined as being part of a planned double or triple autologous or allogeneic transplant protocol. Information on stem cell source was collected as bone marrow or peripheral blood. Combined bone marrow and peripheral blood transplants or cord blood transplants were reported as peripheral blood HSCT. Information on cord blood transplants was collected only as a generic number per year for each individual team. Similarly, information on RIC was collected only as a total for each team and not for individual transplants. Definitions for RIC HSCT followed the recently published definitions.
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Transplant rates
Transplant rates were computed as numbers of HSCT per 10 million inhabitants by disease indication and donor type as listed in Table 1 for each country as defined previously.
14 They were assessed for all HSCT (total HSCT) and separately for allogeneic, autologous, unrelated and RIC allogeneic HSCT. Transplant rates refer to the number of transplants in a given country compared to its own population. The survey cannot make adjustments for patients who cross borders and receive their HSCT in a foreign country. Population data were obtained from the US census office (http://www.census.gov).
Economic factors
In order to assess impact of economic factors on transplant rates in the participating countries, we used GNI per capita as key element. Transplant rates in 2005. There were marked differences in transplant rates between European countries and countries affiliated with EBMT as presented in Figure 1 . These differences relate to all transplants (Figure 1a) , to allogeneic HSCT (Figure 1b) and to autologous HSCT (Figure 1c) . Differences between Eastern and Western European countries have been reported previously. 16 Of interest to note is that countries with similar total transplant rates had similar transplant rates for allogeneic HSCT as well as for autologous HSCT. [18] [19] [20] Detailed information was available this year for the planned multiple transplants. There was a total of 2176 planned multiple autologous HSCT. Compared to 2004, there is no real change. There was a total of 133 planned multiple allogeneic HSCT. Compared to 2004, this corresponds to a decrease of 73%. There were a total of 671 planned double autologous-allogeneic HSCT. This corresponds to 7% of all allogeneic HSCT. Main indications for these planned double transplant programmes were multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease and acute myeloid leukaemia (AML) beyond first complete remission as illustrated in Table 2 .
Disease indications
Stem cell source
Of the 15 278 autologous first transplants, 294 (2%) were bone marrow derived, 14 984 (98%) from peripheral blood stem cells or from combined bone marrow and peripheral blood stem cell transplants (Table 1) . Of the 8890 allogeneic first transplants, 2331 (26%) were bone marrow and 6559 (74%) were peripheral blood stem cell transplants. This corresponds again to an ongoing increase in peripheral blood as stem cell source in allogeneic HSCT; it being 69% in 2004. The proportion of peripheral blood as stem cell source varied depending on donor type. It was 72% for 
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A Gratwohl et al HLA-identical sibling donor transplants, 74% for unrelated donors, 82% for HSCT from other family members and 86% for twin donors. The proportion of peripheral blood as the stem cell source varied for allogeneic HSCT depending on disease indication with a higher proportion of peripheral blood in patients with malignancies. It was 75% for leukaemias, 88% for lymphoproliferative disorders and 89% for solid tumours. It was only 44% for patients with non-malignant diseases, 50% of which were for severe aplastic anaemia.
A total of 395 allogeneic HSCT were cord blood transplants compared to 281 in 2004 and 86 in 1997 when this item was introduced into the activity survey. This corresponds to 4% of all allogeneic transplants. Owing to the design of the survey, no disease specific information on cord blood transplants is available.
Donor type
Absolute numbers in 2005. For the 8890 allogeneic first transplants, HLA-identical siblings were used as donors for 4702 (52%) of the recipients, other family members for 514 (6%) of the recipients, a syngeneic twin for 57 (1%) of the recipients and an unrelated volunteer donor for 3617 (41%) of the recipients. Alternative donors were used for all indications but more commonly for patients with leukaemia's or non-malignant disorders as listed in Table 3 .
Changes over time in use of unrelated HSCT from 1990 to 2005. There was a marked increase in unrelated transplants from 181 HSCT in 1990 181 HSCT in to 3617 in 2005 . This increase was 6% higher than the general increase in allogeneic HSCT during the same time period. The proportion of unrelated transplants was different between European countries in absolute numbers of transplant rates (Figure 2a ) as well as in the proportion of unrelated HSCT amongst allogeneic HSCT (Figure 2b ). The proportion of unrelated donors was especially high for leukaemias as illustrated in Table 3 . Transplant rates for unrelated HSCT (per 10 million inhabitants) suggest a clear dependency on GNI/capita. Transplant rates were higher and increase was more pronounced in absolute numbers in countries with high income as illustrated in Figure 3 . The increase of unrelated HSCT in absolute numbers over the last years is illustrated in Figure 4 with details for AML (Figure 4a ), acute lymphoblastic leukaemia (Figure 4b ), chronic myeloid leukaemia (CML) (Figure 4c ) and severe aplastic anaemia (Figure 4d ). The increase was most marked in AML. As for sibling transplants, the decrease continued for CML. 
Conditioning
Numbers of RIC HSCT continued to increase as reported the year before from 2747 in 2004 to 3301 in 2005. This corresponds to an increase of 20%. This increase was higher and more pronounced in absolute numbers in countries with high income according to GNI per capita. RIC HSCT comprised 34% of all allogeneic HSCT in 2005, with marked variation of RIC HSCT amongst participating countries that ranges from 2 to 100%.
Discussion
This report presents the current state of the art of HSCT in Europe in 2005. It documents the diversity of the procedure, which includes autologous and allogeneic stem cells from the three main sources, bone marrow, peripheral blood and cord blood for a broad range of malignant and non-malignant disorders. [1] [2] [3] [4] [5] [6] [7] It confirms the unbroken increase in transplant rates for allogeneic HSCT, the stable rates of autologous HSCT and the main differences between the participating European countries. Transplant rates were primarily influenced, as previously shown, by the income of the countries with clear dependency from their GNI per capita. [14] [15] [16] Countries with high income, as defined by the World Bank, performed more transplants than countries with less income.
The report highlights the increasing role of unrelated donors in allogeneic HSCT. The increase in unrelated HSCT exceeds the general increase of allogeneic HSCT. It was even more so for some specified disease categories, AML and non-Hodgkin's lymphoma. The increase in transplants and increase in unrelated HSCT was more influenced by GNI/capita with a high increase of unrelated HSCT primarily in countries with high income. The rapid expansion of unrelated donor pools worldwide and the expansion of cord blood banks have changed the outlook of an unrelated donor search. [20] [21] [22] [23] [24] Depending on the selection criteria, up to 80 or 90% of all patients can find a donor in some countries. 25, 26 At the same time, costs for the donor search and costs for the transplant harvest and transfer have increased and add substantially to overall transplant costs. Donors within a country might be the only possible choice for transplant physicians in some countries. Under such circumstances, the gap in transplant rates of unrelated HSCT between countries with high or middle income will likely increase even further in the future.
The observation of a lower proportion of RIC HSCT in economically less advantaged countries fits this observation. RIC HSCT might be less expensive in the early transplant period than standard conditioning HSCT. However, RIC HSCT relies on graft-versus-tumour effects. 11 The ability to monitor and modulate donor chimerism by changes in immunosuppression and donor lymphocyte infusions forms integral part of the procedure. 27 These techniques require laboratory infrastructure, repetitive monitoring and might be more costly long term. With limited resources, standard conditioning might be the preferred choice. This remains a hypothesis. The annual report provides only numbers. More studies are required to gain more insight into the mechanisms behind the differences we have observed. 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Year of transplant Absolute numbers of first transplants High Middle Low The report provides for the first time information on planned double autologous -allogeneic transplants. It is of interest to note, that most of these procedures were performed for patients with multiple myeloma or lymphoma; the diseases for which this was procedure was first suggested. [18] [19] [20] Unexpected, but easy to explain, is the relative high number of planned double autologousallogeneic HSCT for AML beyond first remission. In recent years, several study groups have investigated through prospective randomized studies the value of autologous HSCT compared to intensive chemotherapy. [28] [29] [30] As a consequence, there is a large group of patients with stored cryopreserved cells. They can be used for autologous HSCT instead of re-induction chemotherapy and be followed by a RIC or standard allogeneic HSCT. Concept studies have recently been published.
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As consequence of its design, this survey gives no information on outcome. These data can be reported later, when the information becomes available with sufficient follow-up. Data from these outcome analyses will confirm or refute whether the trends we observe today will be validated by results. Still, as it stands, the survey presents the current status and trends. As such, it is the most accurate and appropriate resource for decision making. This is relevant for patients, physicians, transplant teams and health care providers alike. Gambro BCT, Genzyme, Pfizer, Schering AG, Therakos, AnorMED Inc., GE Healthcare, Pierre Fabre and Zeneus Pharma Ltd.
